Dano D, Lardy-Cleaud A, Monneur A, Quenel-Tueux N, Levy C, Mouret-Reynier MA, et al. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO Open. 2021;6(4): 100220.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abraham HG, Xia Y, Mukherjee B, Merajver SD. Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database. Breast Cancer Res Treat. 2021;185(1):229–38.

Article  PubMed  Google Scholar 

Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT. Inflammatory breast cancer biology: the tumour microenvironment is key. Nat Rev Cancer. 2018;18(8):485–99.

Article  CAS  PubMed  Google Scholar 

Anderson WF, Schairer C, Chen BE, Hance KW, Levine PH. Epidemiology of inflammatory breast cancer (IBC). Breast Dis. 2005;2006(22):9–23.

Google Scholar 

Gudina AT, Copeland G, Soliman AS, Hirko KA. Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program. Breast Cancer Res Treat. 2019;173(3):693–9.

Article  PubMed  Google Scholar 

Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin. 2010;60(6):351–75.

Article  PubMed  Google Scholar 

Soliman AS, Banerjee M, Lo AC, Ismail K, Hablas A, Seifeldin IA, et al. High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah. Egypt Breast J. 2009;15(4):432–4.

Article  PubMed  Google Scholar 

Boussen H, Bouzaiene H, Ben Hassouna J, Gamoudi A, Benna F, Rahal K. Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Semin Oncol. 2008;35(1):17–24.

Article  PubMed  Google Scholar 

Slaoui M, Zoure AA, Mouh FZ, Bensouda Y, El Mzibri M, Bakri Y, et al. Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO). BMC Cancer. 2018;18(1):713.

Article  PubMed  PubMed Central  Google Scholar 

Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, et al. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 2016;27(3):359–66.

Article  PubMed  PubMed Central  Google Scholar 

Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index. J Clin Oncol. 1998;16(12):3731–5.

Article  CAS  PubMed  Google Scholar 

White RE, Warren L, Nakhlis F, Rosenbluth J, Bellon J, Block C, et al. Characteristics associated with inflammatory breast cancer (IBC): an epidemiologic study from a dedicated IBC program. Breast J. 2020;26(9):1688–94.

Article  PubMed  Google Scholar 

Rana HQ, Sacca R, Drogan C, Gutierrez S, Schlosnagle E, Regan MM, et al. Prevalence of germline variants in inflammatory breast cancer. Cancer. 2019;125(13):2194–202.

CAS  PubMed  Google Scholar 

Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL, et al. BRCA mutations in women with inflammatory breast cancer. Cancer. 2018;124(3):466–74.

Article  CAS  PubMed  Google Scholar 

Wecsler JS, Tereffe W, Pedersen RC, Sieffert MR, Mack WJ, Cui H, et al. Lymph node status in inflammatory breast cancer. Breast Cancer Res Treat. 2015;151(1):113–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, et al. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol. 2017;18(4):e228–32.

Article  PubMed  PubMed Central  Google Scholar 

• Jagsi R, Mason G, Overmoyer BA, Woodward WA, Badve S, Schneider RJ, et al. Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research. Breast Cancer Res Treat. 2022;192(2):235–43. This study is important as it provides a more objective system for the diagnosis of IBC which will help to standardize the way in which clinicians diagnose this disease entity.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97(13):966–75.

Article  PubMed  Google Scholar 

Kupstas AR, Hoskin TL, Day CN, Boughey JC, Habermann EB, Hieken TJ. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. Br J Surg. 2020;107(8):1033–41.

Article  CAS  PubMed  Google Scholar 

Garrido-Castro AC, Niman SM, Remolano MC, Rosenbluth JM, Block C, Warren LE, et al. Abstract PS10–34: Clinical outcomes in de novo metastatic HER2-positive inflammatory breast cancer. Cancer Res. 2021;81(4_Supplement):PS10-34-PS10-34.

Article  Google Scholar 

Ge JY, Overmoyer B. Prolonged survival in patients with metastatic HER2-positive inflammatory breast cancer: a case report and review of the literature. Case Rep Oncol. 2021;14(2):1071–9.

Article  PubMed  PubMed Central  Google Scholar 

Wang Z, Wang H, Ding X, Chen X, Shen K. A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer. Ther Adv Med Oncol. 2020;12:1758835920932674.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, et al. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res. 2013;15(6):R112.

Article  PubMed  PubMed Central  Google Scholar 

Tarantino P, Niman SM, Erick TK, Priedigkeit N, Harrison BT, Giordano A, et al. HER2-low inflammatory breast cancer: clinicopathologic features and prognostic implications. Eur J Cancer. 2022;174:277–86.

Article  CAS  PubMed  Google Scholar 

van Uden DJP, Bretveld R, Siesling S, de Wilt JHW, Blanken-Peeters CFJM. Inflammatory breast cancer in the Netherlands; improved survival over the last decades. Breast Cancer Res Treat. 2017;162(2):365–74.

Article  PubMed  Google Scholar 

Hu X, Xiong Y, Villodre E, Song J, Manyam G, Tacam M, et al. Soluble E-cadherin: a novel prognostic biomarker and driver of brain metastasis in inflammatory breast cancer. Cancer Res. 2023;83(5_Supplement):GS5-08.

Bozzetti F, Saccozzi R, De Lena M, Salvadori B. Inflammatory cancer of the breast: analysis of 114 cases. J Surg Oncol. 1981;18(4):355–61.

Article  CAS  PubMed  Google Scholar 

Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40(4):321–9.

Article  CAS  PubMed  Google Scholar 

Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M. D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995;4(4):715–34.

Article  CAS  PubMed  Google Scholar 

• Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, et al. Safety and efficacy of panitumumab plus neoadjuvant chemotherapy in patients with primary HER2-negative inflammatory breast cancer. JAMA Oncol. 2018;4(9):1207–13. This study was important as it showed the highest rate of survival ever reported in triple negative IBC with the use of targeted therapy in conjunction with standard chemotherapy.

Article  PubMed  PubMed Central  Google Scholar 

Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F, et al. EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. Sci Adv. 2022;8(50):eabn7983.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M, Kau SW, Broglio K, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106(5):1000–6.

Article  PubMed  Google Scholar 

Pernas S, Guerriero JL, Naumenko S, Goel S, Regan MM, Hu J, et al. Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. Ther Adv Med Oncol. 2022;14:17588359221113268.

Article  Google Scholar 

Seidman AD, Hudis CA, McCaffrey J, Tong W, Currie V, Moynahan ME, et al. Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer. Semin Oncol. 1997;24(5 Suppl 17):S17-72-S17-76.

Google Scholar 

Cristofanilli M, Buzdar AU, Sneige N, Smith T, Wasaff B, Ibrahim N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001;92(7):1775–82.

Article  CAS  PubMed  Google Scholar 

Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800.

Article  CAS  PubMed  Google Scholar 

von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28.

Article  Google Scholar 

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688–700.